National Guideline Clearinghouse | Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201).

full-text ►
National Guideline Clearinghouse | Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201).

National Institute for Health and Care Excellence (NICE)

October 21, 2013

 

Guideline Title

Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201).

 

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). London (UK): National Institute for Health and Care Excellence (NICE); 2013 Apr. 64 p. (Technology appraisal guidance; no. 278).

 

Guideline Status

This is the current release of the guideline.
This guideline updates two previous versions:

• National Institute for Health and Clinical Excellence (NICE). Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Oct. 38 p. (Technology appraisal guidance; no. 201).
• National Institute for Health and Clinical Excellence (NICE). Omalizumab for severe persistent allergic asthma. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Nov. 28 p. (Technology appraisal guidance; no. 133).